Problem
I. Consider the COVID-19 related patient care experience of large to small healthcare organizations.
II. Pick a broad category of patent-interactive HCO provider for your analysis. (E.G., hospital, specialized practice, ETC.)
III. What strategic considerations would you recommend in making longer term clinical direct contact facilities investments, versus remote patient care? I.E., What should the balance be between investments in buildings VS technology for remote patient care, diagnosis, treatments, ETC.?